Idéal Investisseur Connexion Connexion
Français English
CAC 40 : Market open
7 973,42 pts
-1.33%


Last updated : 20/11/2026 - 12h30
🏠 Home   ➤    Stock news

DBV Technologies shares drop 18.5% over one week, with the €1.57 support in sight

The Châtillon-based biotech is falling mid-session, in a Paris market trending lower amid a sharp correction in technology stocks. Its US approval application is progressing, while its financial position remains under close watch.


DBV Technologies shares drop 18.5% over one week, with the €1.57 support in sight

A stock below all its moving averages, down 18.7% over the week

DBV Technologies shares fell 2.98% to €1.72, in the lower part of the SBF 120, which lost 1.22%. The stock gave up 18.73% over seven days, although it still holds an 8.09% gain over one month, and it trades below its three moving averages.

The price is 7.86% below the MM50 and 37.80% below the MM200, a sign of a medium-term trend still pointing downward.

The RSI at 43 remains neutral, suggesting that the week's decline has not exhausted sellers. The €1.57 support, which the stock had approached in early November, now lies roughly 9% below the current price.

Cash position under watch and a US application under review

When the third-quarter accounts were published on October 28, 2026, the group reported a substantial doubt about its ability to continue as a going concern over the next twelve months. It states that it needs additional capital to finance its operations beyond the third quarter of 2027.

In return, the quarter's $64.5 million loss comes with an advanced regulatory file: the application for approval of the Viaskin Peanut patch in children aged 4 to 7 has been submitted to the FDA, with a decision expected in the fourth quarter of 2026 if priority review is granted.

Reported net short positions reach 3.59% of the share capital, spread across five funds, up 0.20 points over one month. This level shows that some institutional investors remain positioned against the stock, without signaling a massive loss of confidence.

Free · Every morning
Technical market signals, before the opening bell.
Bullish and bearish momentum, analyst changes, stocks to watch — automatically computed from Euronext data.
✓ Before 9 AM every morning ✓ Euronext data ✓ AI-powered analysis


Sector Pharmacie et biotechnologies › Biotechnologies


Context

Period
  • Period: 9M 2026
Key reported figures
  • Revenue: 3,1 millions de dollars
  • Quarterly revenue: 3,1 millions de dollars
  • Revenue growth: -38 %
  • Net income: -162,5 millions de dollars
  • Free cash flow: -159,4 millions de dollars
Risks mentioned
  • Substantial doubt exists about the Company's ability to continue as a going concern within twelve months
  • Manufacturing remediation activities ongoing at Fareva following FDA Warning Letter of April 2026
  • Company requires additional capital to fund operations beyond Q3 2027
Opportunities identified
  • BLA for VIASKIN Peanut Patch in children aged 4-7 years submitted with Priority Review requested, expected FDA determination in Q4 2026
  • Planned BLA submission for toddlers aged 1-3 years in 2027 with potential rolling submission approach
  • Recent $50 million ADS financing completed and $150 million ATM program refreshed to support operations and commercial readiness

The information presented in this article is provided for informational purposes only and does not constitute an investment recommendation, an incentive to buy or sell a financial asset, or investment advice. Readers are invited to conduct their own research before making any decision.

Investments in the stock market involve risks, including the risk of capital loss. Past performance of an asset or market is no guarantee of future results. Any investment decision should be made taking into account your personal financial situation, objectives and risk tolerance.

Advertisement
Every morning
Technical market signals,
before the opening bell.
CAC 40 · SBF 120 · Signals · Analysts
🤖
Today's edition — pre-market
CAC 40
7 702
-0,87%
SBF 120
5 827
-0,87%
📈 Bullish signals
+5,2%
+1,8%
+0,9%
📉 Bearish signals
-14%
-5,7%
🔄 Analyst opinions
▲ 35 €
▼ 80 €
Sign up to see everything →
Before 9 AM every morning
Euronext data
AI-powered analysis





BOURSE · Chaque matin
La synthèse bourse,
avant l'ouverture.
Notre moteur analyse chaque nuit le CAC 40 et le SBF 120. Ce qui mérite attention remonte directement dans votre boîte mail. Gratuit.
✓ Avant 9h00 ✓ 1000+ inscrits ✓ 100% gratuit
Gratuit · chaque matin
Ne ratez plus rien sur vos actions
La tendance derrière les cours sur les valeurs Euronext, chaque matin avant 9h.
tendance · 6 séances
📈les valeurs en mouvement, sur la durée
🎯les objectifs d'analystes qui évoluent
📰les actualités qui font bouger les cours